Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Background: Immune checkpoint inhibitors (ICIs) represent a new therapeutic standard for an increasing number of tumor entities. Nevertheless, individual response and outcome to ICI is very heterogeneous, and the identification of the ideal ICI candidate has remained one of the major issues. Sarcope...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Loosen, Sven H., van den Bosch, Vincent, Gorgulho, Joao, Schulze-Hagen, Maximilian, Kandler, Jennis, Jördens, Markus S., Tacke, Frank, Loberg, Christina, Antoch, Gerald, Brümmendorf, Tim, Neumann, Ulf P., Kuhl, Christiane, Luedde, Tom, Roderburg, Christoph
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036296/
https://ncbi.nlm.nih.gov/pubmed/33806224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10071361
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars